Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.
At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude.
The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.The Director, National Corporate Accounts (DNCA), Managed Markets, is responsible for ensuring timely, consistent, and frictionless access by addressing non-clinical financial and operational barriers within assigned, prioritized accounts. This role involves managing contracts, total cost of care, MID dynamics, formulary, pathway, workflow integration, and more. This position reports to the Senior Director, GPO/Corporate Accounts/Strategic Partnerships, Managed Markets.
Essential Job Functions
- Access Management: Ensure seamless access by addressing non-clinical financial and operational barriers within assigned accounts.
- Account Management: Lead engagement and pull through with Access Decision-Makers at assigned Organized Customers including, but not limited to large GPO Member Community Practices and Aggregators (i.e., Texas Oncology, Florida Cancer, OneOncology, Athena, AON), Select Academic institutions with broad networks and market access influence (i.e., Moffitt, City of Hope, Dana Farber, UPMC, Mayo Clinic), Provider Pathways (i.e., ClinicalPath, Philips, Value Pathways), or other relevant customers as per business needs.
- Partnership Development: Build and maintain “entity to entity” partnerships with access decision-makers (C-Suite, Pharmacy, Administration).
- Cross-Functional Collaboration: Work closely with the cross-functional field team (Payer, Sales, Regional Marketing, Field Medical, Field Reimbursement) and the broader market access team to ensure cohesive customer relationships and insights capture.
- Strategic Agility: Identify and prioritize opportunities for greatest impact with limited resources.
- Customer Relationship Management: Foster longitudinal, cohesive customer relationships grounded in shared goals.
Job Requirements
- 10+ years of relevant experience and customer relationships in oncology with 5+ years of those in oncology / rare disease market access preferred.
- Demonstrated strategic agility, strong relationship-building skills, and the ability to work effectively within a team.
- Proven track record in managing complex accounts and building strategic partnerships.
- Strong understanding of non-clinical financial and operational barriers in healthcare.
- Excellent communication and interpersonal skills.
- Ability to work independently and as part of a team.
- Willingness to travel as needed (up to 75%).
The base range for a Director is $218,749 - $249,500 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.
Kura’s Values that are used for candidate selection and performance assessments:
- We work as one for patients
- We are goal-focused and deliver with excellence
- We are science-driven courageous innovators
- We strive to bring out the best in each other and ourselves
The Kura Package
- Career advancement/ development opportunities
- Competitive comp package
- Bonus
- 401K + Employer contributions
- Generous stock options
- ESPP Plan
- 20 days of PTO to start
- 18 Holidays (Including Summer & Winter Break)
- Generous Benefits Package with a variety of plans available with a substantial employer match
- Paid Paternity/Maternity Leave
- In-Office Catered lunches
- Home Office Setup
- Lifestyle Spending Stipend
- Commuter Stipend (Boston Office)
- Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!
Kura Oncology is a clinical-stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of blood cancers and solid tumors. The company’s diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s approach to drug development is focused on rapidly translating novel science into life-saving medicines.
Our goal is to help patients with cancer lead better, longer lives. Kura Oncology has offices in San Diego, California, and Boston, Massachusetts.Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of R/R NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001).
The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001).
For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.
